INS and cancer: The prevalence of sarcopenic obesity is considered a novel factor of great clinical relevance in cancer patients, leading to postoperative complications, worse functional status, and shorter survival possibly mediated by interactions among pathophysiological mechanisms (inflammation, insulin resistance, dysregulation of myokines and pro-inflammatory cytokines).